Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. It offers antibodies, which include nuclear receptors and epigenetics and sells antibodies against proteins and transcription factors involved in vascular inflammation. The company was founded by Akiyuki Furuya on February 1, 2001 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company